Overview and Strategy

Synageva BioPharma's ultimate goal is to improve patient lives by providing access to breakthrough novel, next generation (i.e. significantly improved), and certain follow on protein therapeutics. Synageva's proprietary platform technologies, including SEPTM, provide a number of sustainable competitive advantages for developing and commercializing these therapeutics including: high expression levels, more efficient purification processes, significantly reduced costs of production, rapid scalability, and consistency of end product. Our platform has already demonstrated its ability to produce a wide array of human therapeutic proteins including monoclonal antibodies (mAbs), cytokines, and other biotherapeutics.

We currently have multiple compounds in development, including 2 monoclonal antibodies with enhanced ADCC activity, novel therapeutic proteins, and several cytokines including one with unique efficacy advantages. The commercialization strategy for these product candidates is designed to maximize our ability to rapidly develop and bring them to market so that they can address patients' unmet medical needs. The key elements of the strategy are to:

  1. Establish partnerships to co-develop and commercialize select product candidates in large specialty markets
  2. Independently develop and commercialize select novel product candidates that target high value orphan specialty markets
  3. Establish partnerships to express proteins from other companies wanting to leverage the unique glycosylation advantages and other characteristics of the SEPTM